Company ProfilePremium

Aster DM Healthcare Limited

Company Profile Analysis

Tickers: ASTERDM.NS, 540975.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aster DM Healthcare Limited - Company showcase

Year Founded & Workforce

1987

45,000 Employees

Aster DM Healthcare Limited logo

Aster DM Healthcare Limited Employee Contacts

35 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Aster DM Healthcare Limited Overview

FieldDetailSource
Current legal nameAster DM Quality Care LimitedExchange filing, Jul 2026
Former namesAster DM Healthcare Private Limited (2008); Aster DM Healthcare Limited (after conversion to public company; until 3 Jul 2026)InCred/IIFL company profile; Screener
Founding of group1987, when Dr. Azad Moopen opened a single clinic in DubaiBloomberg via Gulf News, Nov 2024
Indian incorporation18 January 2008, as a private limited companyCompany profile (InCred Money)
Incorporation jurisdictionIndia (Companies Act). Merger scheme sanctioned by NCLT Hyderabad BenchNCLT order coverage, Jan 2026
Headquarters / corporate officeBengaluru, Karnataka (press releases are datelined Bengaluru).Q4 FY26 and Q1 FY27 press releases
Exchanges and tickersNSE: ASTERDM; BSE: 540975NSE/BSE filings
ISININE914M01019Exchange data (Bigul)
CUSIPNot applicable (no US listing)—
Fiscal year end31 MarchCompany filings
Statutory auditorDeloitte Haskins & Sells (limited review of Q1 FY27 results)Q1 FY27 board outcome, 5 Aug 2026
Shares outstanding871,672,439 equity shares of INR 10 each after merger allotment (up from 518,121,029)SAST disclosure, Jul 2026
Employees (merged entity)Over 45,000 professionalsMerger completion disclosure, 2 Jul 2026
Employees (3-year trend)Standalone India headcount trend is not publicly disclosed in the sources reviewed. Pre-separation group (incl. GCC) had 34,239 staffAster DM Foundation page (GCC-era)
Market capitalisationAbout INR 61,793 crore at INR 708.90 per share on 1 Oct 2026IIFL / InCred Money
Credit ratingsICRA AA (Stable) / A1+ (Jul 2026); CRISIL AA+ (Stable) / A1+ (Jul 2026)ICRA and CRISIL rationales
Website (listed entity IR)asterdmhealthcare.in (IR); hospital brand sites remain separateCompany IR pages

Aster DM Quality Care is a hospital-led integrated healthcare platform in India. It was formed on 1 July 2026 by merging the founder-led Aster DM Healthcare with Blackstone-controlled Quality Care India. The combined network spans 39 hospitals across 28 cities and more than 10,890 beds under four brands: Aster, CARE Hospitals, KIMSHEALTH and Evercare [Src: Q1 FY27 press release, Aug 2026]. Its footprint is concentrated in South and Central India and Bangladesh, with deliberate exposure to Tier-2 and Tier-3 cities such as Nagpur, Vijayawada and Raipur. Those markets have weaker incumbents and faster growth in insurance and private-hospital demand. On FY26 pro-forma figures, the platform generated INR 9,273 crore of revenue and INR 2,013 crore of operating EBITDA (21.7% margin) [Src: FY26 results, Apr 2026]. That places it in the top three Indian hospital chains by scale. The investment case rests on four things: brownfield-heavy bed additions, merger synergies, clinical depth in quaternary specialties, and joint promoter-PE governance. The main risks are integration execution and a rich valuation.


What the Company Does

The company owns and operates multi-specialty and super-specialty hospitals. It also runs clinics, a diagnostics network (Aster Labs and patient experience centres) and digital health channels. Retail pharmacy is run in a franchise-like format: the Aster Pharmacy stores in India are operated by Alfaone Retail Pharmacies Private Limited under a brand licence from Aster [Src: company IR "About Aster DM" page].

Before the merger, Aster DM Healthcare described itself as one of the largest healthcare providers in India. It said it covered primary, secondary, tertiary and quaternary care through 19 hospitals with about 4,867–4,994 beds, 13 clinics, roughly 212–217 brand-licensed pharmacies and 232–243 labs and patient experience centres across five to six states [Src: company IR page, various 2024–25 versions]. By Q3 FY26, standalone Aster reported 20 hospitals [Src: Q3 FY26 press release, Feb 2026]. Labs and PECs reached 321 in Q1 FY27 [Src: AskFuzz aggregation of Q1 FY27 presentation].

Business Model and Revenue Model

The business is overwhelmingly a service model. Revenue comes from inpatient (IP) and outpatient (OP) hospital services, priced per episode or per day of stay and paid by cash/self-pay patients, private insurers and TPAs, government schemes and international patients. There is no meaningful product, subscription or licensing revenue at group level. The exceptions are:

  • Brand-licence economics from the Alfaone-operated pharmacies.

  • Diagnostics revenue from Aster Labs, which is fee-for-service.

Key operating drivers disclosed by the company are:

  • Occupancy: 61% for Aster standalone in FY26; 64% blended pro-forma in Q1 FY27.

  • Average revenue per occupied bed (ARPOB): INR 51,800 for Aster in FY26.

  • Average revenue per inpatient (ARPP IP): INR 144,064 for Aster in Q1 FY27, up 9% YoY.

  • Patient volumes: about 2.01 million pro-forma in Q1 FY27, up 13% YoY.

[Src: FY26 results coverage (ScanX); Q1 FY27 press release and transcript summaries.]

Value-Chain Position and Customers

The company sits at the provider end of the healthcare value chain. It buys pharmaceuticals, consumables and equipment from suppliers. It employs or contracts clinicians and bills payers. Customers fall into five groups:

  • Domestic self-pay patients

  • Privately insured patients, a growing share of the market

  • Beneficiaries of government and public-sector schemes

  • Corporate tie-ups

  • International "medical value travel" (MVT) patients

MVT is material in the Kerala cluster. In Q2 FY26, MVT revenue rose 67% quarter on quarter [Src: FilingReader summary of Q2 FY26 results].

Company Self-Description vs. Independent Characterisation

Company language (paraphrased). Management positions the merged entity as one of India's leading integrated healthcare providers. It cites four trusted brands, a focus on clinical excellence, digitally enabled care and a bias toward high-quality clinical outcomes. It emphasises expanding specialist access to underserved Tier-2 and Tier-3 cities [Src: merger completion releases, Jul 2026].

Independent characterisation. In practice the merged entity is a regional-cluster hospital operator with two strong cores:

  1. Kerala. This is Aster's historic base: Aster Medcity Kochi, Aster MIMS Calicut, Kannur and Kasaragod, and now KIMSHEALTH Thiruvananthapuram.

  2. Telangana / Andhra Pradesh / Central India. This is the CARE Hospitals footprint plus Aster Ramesh and Aster Prime.

The Bengaluru cluster (Aster CMI, Aster RV, Aster Whitefield) and Bangladesh (Evercare) are secondary pillars. Diagnostics and pharmacy are adjacencies, not profit engines. Aster Labs only reached a 12.8% operating EBITDA margin in FY26, up from 7.6% in FY25 [Src: AGM highlights, Oct 2026].

The platform's economic character is mid-ARPOB, volume-led and cluster-dense. It differs from the premium metro-ARPOB model of Max Healthcare (about INR 77,800 ARPOB in FY26) [Src: Upstox peer comparison, 2026].

Strategy

Stated Strategic Themes (paraphrased from 2026 disclosures)

  1. Scale to top-three in India. The merger is positioned as creating one of the top three hospital chains in India by beds and revenue [Src: merger releases].

  2. Tier-2 and Tier-3 access. Expand specialist care, advanced treatment and medical technology in cities such as Nagpur, Vijayawada and Raipur [Src: merger completion disclosure].

  3. Brownfield-led capacity growth. Pipeline of about 4,170 beds to exceed 15,000 beds, with about 53% brownfield to raise capital efficiency [Src: AGM highlights, Oct 2026].

  4. Clinical excellence and centres of excellence. Shared protocols, multidisciplinary consultations and integrated centres of excellence across the four brands [Src: AskFuzz merger summary].

  5. Technology. Investment in robotics and radiation therapy (Gamma Knife, ZAP), digital health platforms and exploration of agentic AI [Src: AGM].

  6. Synergies. Procurement, digital health and clinical collaboration [Src: merger completion]. One aggregator cites an expected 10–15% EBITDA uplift [Src: AskFuzz]. ICICI Direct references a figure of about INR 150–200 crore in its Aug 2026 update, though the context is only partially visible.

  7. Capital discipline. Management confirmed no further dividends or bonus issues are planned for now, prioritising capital deployment [Src: AGM highlights].

Initiative Register (last 24 months)

DateInitiativeDetailSource
Nov 2024Merger with QCILAll-stock; 977 Aster shares per 1,000 QCIL sharesCompany; Mint
May–Jun 2025Organic expansion planAbout 2,100 Aster beds (of about 3,300 combined) for about INR 1,878–1,900 croreOutlook Business; Towards Healthcare
Oct 2025Kasaragod launch263–264 beds, North KeralaQ2 FY26
Apr 2026Enlarged expansion plan4,080 beds for about INR 4,000 crore (2,368 by Aster)Outlook Business, Apr 2026
Jul 2026Merger completion and new organisationRegional CEOs; CDO; Group CPO; Group LegalBoard outcome
Aug 2026FY30 capacity ambition4,179 beds to reach 15,077Q1 FY27 presentation
Sep 2026Capital allocation frameworkINR 6,900 crore over FY27–FY29AGM addendum
OngoingDiagnostics profitability-firstLabs margin 7.6% to 12.8%AGM
OngoingPharmacy profitability over expansionManagement stance on labs and pharmacyDigitalHealthNews

Medium-Term Targets and Guidance

No formal numerical revenue or margin guidance was provided in statutory results [Src: Quartr Q2 FY26 summary]. Quantified intentions are:

  • Bed capacity above 15,000.

  • Capital deployment of INR 1,900 crore in FY27, INR 3,000 crore in FY28 and INR 2,000 crore in FY29.

  • Merger benefits expected from FY27 onward [Src: Outlook Business interview, 2025].

Products & Services

Hospital groups do not publish SKU-style catalogues or list prices. Pricing is episode-based and payer-negotiated, and is not publicly disclosed. The portfolio below is organised by brand, facility and service line. Facility bed counts and dates are given where verified. Facilities listed from general knowledge without a verified source are flagged "(verify)".

Brand: Aster (legacy Aster DM Healthcare India)

Facility / offeringLocationLevel of care / notesStatus / latest dataSource
Aster MedcityKochi, KeralaQuaternary flagship; 100-bed expansion underway; margin about 30%Operational since 2014Company releases
Aster MIMS CalicutKozhikode, KeralaTertiary/quaternaryOperationalCompany releases
Aster MIMS KannurKannur, KeralaTertiary; launched with 302 beds; 100-bed expansion plannedOperational since Q4 FY19Company profile
Aster MIMS KasaragodKasaragod, KeralaMulti-specialty, about 263–264 bedsCommenced 2 Oct 2025Q2 FY26 presentation
Aster MIMS KottakkalMalappuram, KeralaSecondary/tertiary (verify)OperationalGeneral knowledge
Aster Capital HospitalThiruvananthapuram, KeralaGreenfield tertiary, 454 bedsUnder constructionApr 2026 release
Aster CMIBengaluru (Hebbal)Tertiary/quaternary; +350-bed expansionOperationalApr 2026 release
Aster RVBengaluru (JP Nagar)Tertiary (verify)OperationalGeneral knowledge
Aster WhitefieldBengaluruMulti-specialty; +159-bed expansion (H2 FY26)OperationalQ2 FY26 presentation
Aster Sarjapur Road hospitalBengaluruGreenfield, 430 beds, about INR 480 crore investment; SPV Aster DM-Super Specialty Hospital (Sarjapur) Pvt Ltd (INR 45.09 crore invested in Q1 FY27)Under constructionDigitalHealthNews; Q1 FY27 standalone notes
Aster YeshwanthpurBengaluruMulti-specialty, 500 bedsPipelineQ2 FY26 presentation; Apr 2026 release
Aster AadharKolhapur, MaharashtraMulti-specialty; held via Prerana Hospital Ltd; remaining 13% stake acquiredOperationalBusiness Standard topic page; ICRA
Aster Ramesh HospitalsVijayawada, Guntur and others, Andhra PradeshMulti-specialty; Aster Ramesh Ongole slated to commence in H2 FY26OperationalQ2 FY26 presentation
Aster PrimeHyderabad, TelanganaMulti-specialty (verify)OperationalGeneral knowledge
Aster Women & ChildrenHyderabad300-bed mother-and-child hospital; about INR 220 crore investment; target H1 FY27Under developmentIIFL; Q2 FY26 presentation
Aster Clinics (13)Kerala/Karnataka and othersPrimary careOperationalCompany IR page
Aster Labs and PECsMulti-stateDiagnostics; 321 labs and PECs (Q1 FY27)OperationalQ1 FY27 data aggregation
Aster Pharmacy (India)Multi-stateAbout 212–217 stores operated by Alfaone Retail Pharmacies under brand licenceOperationalCompany IR page
Aster@HomeBengaluru/KeralaHome care servicesOperationalDigitalHealthNews
Aster Health appPan-IndiaAppointments, e-pharmacy, digital recordsLiveDigitalHealthNews

Brand: CARE Hospitals (QCIL legacy)

CARE Hospitals was founded in 1997 in Hyderabad. It is QCIL's largest brand, with a footprint across Telangana, Andhra Pradesh, Odisha, Chhattisgarh, Maharashtra (Nagpur) and Madhya Pradesh (Indore) [Src: CB Insights for founding year; footprint per general knowledge — verify facility list]. Post-merger, management named Nagpur, Vijayawada and Raipur as Tier-2 expansion targets [Src: merger completion disclosure]. A facility-level bed register for CARE is not publicly disclosed in the reviewed sources.

Brand: KIMSHEALTH (QCIL legacy)

KIMSHEALTH is a tertiary/quaternary brand anchored in Thiruvananthapuram, Kerala. It strengthens the Kerala cluster alongside Aster Medcity and the MIMS hospitals. It is distinct from Krishna Institute of Medical Sciences (KIMS, a listed peer). The facility register is not publicly disclosed in the reviewed sources.

Brand: Evercare (QCIL legacy, Bangladesh)

Evercare operates hospitals in Bangladesh, at Dhaka and Chattogram per general knowledge (verify). QCIL describes its network as spanning India and Bangladesh [Src: Wealthy.in citing company]. A dedicated Bangladesh regional CEO was appointed on 1 July 2026 [Src: board outcome].

Flagship Clinical Technologies and Programs

Technology / programDescriptionSource
Gamma KnifeStereotactic radiosurgery platform18th AGM disclosures
ZAP stereotactic radiosurgerySelf-shielded radiosurgery system for brain lesions18th AGM disclosures
Robotic surgical systemsMulti-specialty robotics across network18th AGM; merger completion release
Structural heart (TAVI, valve-in-valve)First valve-in-valve with a self-expanding Evolut valve at Aster WhitefieldQ2 FY26 presentation
Agentic AI explorationFor patient engagement, diagnostics and precision medicine18th AGM disclosures
International patient (MVT) programKerala-centred; MVT revenue +67% QoQ in Q2 FY26FilingReader Q2 FY26

Financial Narrative

Basis of Preparation

Three bases are used below:

  • Aggregator data (StockAnalysis, consolidated, INR million converted to crore). Provides a consistent five-year series.

Company-reported figures: Used for revenue, company-defined operating EBITDA and net profit where available.

Ratings-agency data (ICRA, CRISIL): Used for balance-sheet items.

FY22 includes the GCC business and is not comparable with FY23–FY26, which reflect continuing India operations after the GCC business was reclassified as discontinued. Blank cells mean the item is not publicly disclosed in the sources reviewed.

Income Statement

[Src: StockAnalysis income statement (FY22–FY26); company FY26 results (operating EBITDA, net profit INR 464 crore, normalised PAT INR 421 crore, +18%). FY25 net profit of INR 5,407.89 crore includes the GCC divestment gain (Towards Healthcare citing company). FY25 normalised PAT is derived from the stated 18% growth (421/1.18 ≈ 357) and should be treated as derived.]

EPS. Q2 FY26 basic EPS was INR 2.12 [Src: AlphaStreet]. Full-year FY26 EPS is not captured in the sources reviewed. A derived estimate of about INR 9.0 per share (INR 464 crore over about 51.8 crore pre-merger shares) is indicative only. FY25 EPS was inflated by the GCC gain. Diluted EPS is not publicly disclosed in the sources reviewed.

Margins

Revenue CAGR.

  • FY24–FY26: 12.0% (derived: 4,643 / 3,699 over two years).

  • FY23–FY26: 15.7% (derived).

  • Management's five-year claim: about 20% revenue CAGR and about 38% operating EBITDA CAGR [Src: Q2 FY26 earnings summary, Quartr]. PL Capital separately cites about 30% EBITDA CAGR over FY22–FY25 [Src: PL Capital Q2 FY26 note].

Commentary. The defining financial story of FY23–FY26 is margin expansion on a re-based, India-only asset base. Aggregator EBITDA margin rose about 570 bps, from 13.7% in FY23 to 19.4% in FY26. Company-defined operating EBITDA margin reached 20.4% in FY26. Three drivers explain this:

  1. Ramp-up of maturing Kerala and Bengaluru hospitals. Matured-hospital margins are about 25–26.5%.

  2. Case-mix and ARPOB improvement. ARPOB reached INR 51,800 in FY26.

  3. Turnaround in diagnostics. Aster Labs moved from 7.6% to 12.8% operating EBITDA margin.

The inflection to watch is FY27. Two new hospitals (Kasaragod and Whitefield) and a Hyderabad women-and-children hospital will dilute margins initially; management already reports Kasaragod-excluded EBITDA. Merger-related costs are also a drag: INR 109.79 crore of exceptional professional fees and merger costs in Q1 FY27 standalone [Src: Q1 FY27 results]. Normalised PAT fell from INR 200 crore in Q2 FY26 to INR 125 crore in Q1 FY27 [Src: AskFuzz aggregation]. Some of these numbers come from an aggregator summary and should be cross-checked against filings.

Balance Sheet

[Src: FY25 debt (INR 2,017.8 crore), cash (INR 1,380.5 crore) and leverage ratios from ICRA rationale, Oct 2025. FY26 debt (INR 2,220 crore) and cash (INR 228 crore) from ICICI Direct company update, Aug 2026.]

Source conflict. ICICI Direct's FY26 cash figure of INR 228 crore implies FY26 net debt of about INR 1,992 crore. ICICI Direct also reports that Aster had a INR 511 crore net cash position at 30 June 2026, against QCIL debt of INR 1,673 crore, for combined net debt of INR 1,162 crore. The difference most likely reflects classification: lease liabilities included in "debt" and treasury investments or fixed deposits excluded from "cash". Both figures are reported here. The INR 1,162 crore combined net debt at 30 June 2026 is the more relevant post-merger number. CRISIL estimates pro-forma gearing at about 0.6x at 31 March 2026 [Src: CRISIL rationale, Jul 2026].

Total assets, equity, goodwill and intangibles, and working capital for the five-year span are not publicly disclosed in the sources reviewed. Goodwill will step up materially in FY27 under merger accounting.

Cash Flow

[Src: About INR 320 crore of expansion capex spent in FY25 per company statements via Towards Healthcare. INR 350–400 crore of capex incurred as of 30 Jun 2025 per ICRA. Special dividend outflow of about INR 5,894 crore in April 2024 (FY25) per directors' report.]

Operating cash flow, free cash flow and buybacks are not publicly disclosed in the sources reviewed. There have been no buybacks.

Forward capital deployment (company addendum to AGM notice). About INR 1,900 crore in FY27, INR 3,000 crore in FY28 and INR 2,000 crore in FY29, totalling about INR 6,900 crore [Src: AGM addendum, Sep 2026].

Ratios

Point-in-time ratios:

Current ratio, ROA, asset turnover and cash conversion cycle are not publicly disclosed in the sources reviewed. Hospital working capital is structurally light for cash patients, but insurance and scheme receivables extend it.

Interpretation of ROE vs ROCE. The gap between the low statutory ROE (about 7.75%) and management's pro-forma ROCE (about 23%) reflects two things. First, the equity base is inflated by retained GCC proceeds and merger equity. Second, management's ROCE excludes capital-work-in-progress and non-operating cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY24FY25FY26

Revenue from operations (INR Cr)

3,6994,1384,643

Revenue YoY growth (%)

23.511.912.2

Operating EBITDA, company-defined (INR Cr)

—806947

Operating EBITDA margin (%)

—19.520.4

Revenue by Segment and Segment Margins & Growth (%) — Combined pro-forma revenue

MetricFY24FY26

Combined pro-forma revenue (INR Cr)

7,3149,273

of which Aster (INR Cr)

3,6994,643

of which QCIL, derived (INR Cr)

3,6154,630

Combined pro-forma operating EBITDA (INR Cr)

1,3962,013

of which Aster operating EBITDA (INR Cr)

—947

of which QCIL operating EBITDA, derived (INR Cr)

—1,066

Combined operating EBITDA margin (%)

19.121.7

Revenue by Segment

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Aster revenue (INR Cr)

1,0781,1971,1861,1821,311

Aster operating EBITDA (INR Cr)

—263237244279

QCIL revenue (INR Cr)

—1,1931,181—1,287

QCIL operating EBITDA (INR Cr)

—287——299

Combined pro-forma revenue (INR Cr)

—2,3902,3662,3612,597

Combined pro-forma operating EBITDA (INR Cr)

—550503—576

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Business Units

UnitLatest disclosed KPIPeriodSource

Kerala cluster

Record quarterly revenue INR 620 crore (+11–12% YoY); operating EBITDA +19% YoY; margin 26.8% (vs 25.0%)

Q2 FY26

Q2 FY26 release

Kerala cluster

Revenue +20% YoY; operating EBITDA +18% YoY

Q3 FY26

Indian Pharma Post

Aster Medcity (Kochi)

Revenue +24% YoY; operating EBITDA +33%; margin 30%

Q3 FY26

Q3 FY26 release

Aster Medcity (Kochi)

Revenue +16% YoY; operating EBITDA +26%

Q4 FY26

Q4 FY26 release

Aster MIMS Calicut

Revenue +14% YoY; EBITDA +20%; margin 26%

Q3 FY26

Q3 FY26 release

Aster MIMS Calicut

Revenue +21% YoY; EBITDA +41%

Q4 FY26

Q4 FY26 release

Aster Whitefield (Bengaluru)

Revenue +27% YoY

Q2 FY26

Q2 FY26 presentation

Aster Whitefield (Bengaluru)

Revenue +15% YoY; EBITDA +38%

Q4 FY26

Q4 FY26 release

Andhra & Telangana cluster

Operating EBITDA margin 13.2% (vs 7.9% in Q1 FY26)

Q2 FY26

Q2 FY26 release

Andhra & Telangana cluster

Revenue +13% YoY; EBITDA +7%

Q3 FY26

Q3 FY26 release

Core hospitals & clinics

Operating EBITDA margin 24.4% (vs 24.0%)

Q2 FY26

Q2 FY26 release

Matured hospitals

Operating EBITDA margin 26.5% (Q2 FY26); 25.1% (Q3 FY26)

Q2–Q3 FY26

Releases

Aster Labs

Revenue +15% YoY; margin 17.8%

Q2 FY26

Investywise summary

Aster Labs

Revenue +18% YoY

Q4 FY26

Q4 FY26 release

Aster Labs

Full-year operating EBITDA margin 12.8% (vs 7.6% in FY25)

FY26

AGM highlights

Margin Analysis (%)

MetricFY22FY23FY24FY25FY26

Revenue, INR Cr (aggregator)

10,2532,9943,6994,1394,643

Revenue YoY growth, %

19.1-70.823.511.912.2

Gross profit, INR Cr

3,6671,5591,9762,2922,719

Operating income (EBIT), INR Cr

844257358517637

EBITDA, INR Cr (aggregator definition)

1,211410533706901

Operating EBITDA, INR Cr (company definition)

———806947

D&A, INR Cr

367153175189264

Interest expense, INR Cr

25585106108123

Net profit attributable, INR Cr (company)

———5,408464

Normalised PAT, INR Cr (company)

———357421

Dividend per share declared for the FY, INR

———1183

Margin Analysis (%) — Gross margin, %

MetricFY22FY23FY24FY25FY26

Gross margin, % (derived)

35.852.153.455.458.6

Operating (EBIT) margin, % (derived)

8.28.69.712.513.7

EBITDA margin, % (aggregator)

11.8113.7014.4117.0619.41

Operating EBITDA margin, % (company)

———19.520.4

Net margin on normalised PAT, % (derived)

———8.69.1

Financial Ratios (x)

MetricFY24FY25FY26

Total debt, INR Cr

—2,0182,220

Cash and equivalents, INR Cr

—1,381228

Net debt, INR Cr (derived)

—6371,992

Total debt to OPBDITA, x

2.12.6—

Net debt to OPBDITA, x

2.10.8—

Financial Analysis

MetricFY25

Capex, INR Cr (company-indicated)

320

Dividends paid, INR Cr

5,894

Financial Ratios (x) (FY22–FY26)

MetricFY22FY23FY24FY25FY26

Interest coverage, EBIT to interest, x (derived)

3.33.03.44.85.2

EBITDA to interest, x (derived)

4.74.85.06.57.3

Financial Analysis — ROE

RatioValueAs ofSource

ROE (TTM)

7.75%

Sep 2026

Value Research

ROCE (TTM)

11.57%

Sep–Oct 2026

Screener

Pro-forma ROCE, merged entity

22.9%

Q1 FY27

Company (Investywise summary)

Pro-forma ROCE (management)

Above 22%

Q2 FY26

Q2 FY26 release

ROCE change, Aster standalone

+330 bps YoY

FY26

AGM highlights (ScanX)

Pro-forma gearing

About 0.6x

31 Mar 2026

CRISIL

Geographic Revenue

MetricFY22FY23FY24FY25FY26

Consolidated reported revenue, INR Cr

10,2532,9943,6994,1394,643

Region / Cluster Details

Region / clusterConstituentsLatest disclosed revenue signalGrowth signalSource

Kerala

Aster Medcity, MIMS Calicut, Kannur, Kottakkal, Kasaragod; KIMSHEALTH

INR 620 crore (Q2 FY26, Aster only)

+20% YoY (Q3 FY26)

Q2 and Q3 FY26 releases

Karnataka (Bengaluru)

Aster CMI, RV, Whitefield; Sarjapur and Yeshwanthpur in pipeline

Not disclosed in absolute terms

Whitefield +15% to +27% YoY

Q2 and Q4 FY26

Andhra Pradesh & Telangana

Aster Ramesh, Aster Prime; CARE Hyderabad cluster

—

Aster A&T +13% YoY (Q3 FY26)

Q3 FY26

Maharashtra

Aster Aadhar Kolhapur; CARE Nagpur (and others, verify)

———

Central/East India

CARE Raipur, Bhubaneswar, Indore (verify)

—

QCIL emerging units +47% YoY

Q1 FY27 release

Bangladesh

Evercare Dhaka, Chattogram (verify)

———

“—” = not publicly disclosed.

Executive Leadership

Executive Leadership Team

NameTitleEffectiveBackground (as disclosed)Source

Dr. Azad Moopen

Executive Chairman; Executive Director (15 Apr 2026 to 28 May 2028)

Chairman since founding; ED term from Apr 2026

Founder (1987). Previously Founder Chairman & MD

CB Insights; BW Healthcare

Varun Khanna

Managing Director & Group CEO (five-year term)

1 Jul 2026

Formerly Group MD of QCIL (CARE, KIMSHEALTH, Evercare); about three decades of cross-sector experience

DigitalHealthNews; exchange filing

Alisha Moopen

Board member (Moopen family nominee). Previously Deputy MD, Aster DM Healthcare India. Also MD & CEO of the separate Aster GCC business

—

Second-generation promoter

DigitalHealthNews; The National, Oct 2026

Sunil Kumar M R

Group CFO & Head of Investor Relations

19 Jul 2026

Previously CFO, Aster

FilingReader

Pawan Kumar

Chief Executive, India II

1 Jul 2026

—

FilingReader

Vinod Raman

Chief Digital Officer

1 Jul 2026

—

FilingReader

Regional CEOs, India I and India III; CEO Bangladesh

Regional chief executives

1 Jul 2026

Names not captured in reviewed sources

Board outcome

Group Chief People Officer; Group Legal Officer

New roles

1 Jul 2026

Names not captured

Board outcome

Hemish Purushottam

Company Secretary & Compliance Officer (signatory on 2026 filings)

——

NSE filing, Mar 2026

Dr. Nitish Shetty

CEO, Aster DM Healthcare India (pre-merger)

—

Post-merger role not confirmed in reviewed sources

Company releases 2024–25

Hitesh Dhaddha

Chief Investor Relations and M&A Officer

Exited 18 Jul 2026 (personal reasons)

—

AskFuzz; FilingReader

Board of Directors

NameCategoryChangeSource

Dr. Azad Moopen

Executive Chairman

Continuing

Company

Varun Khanna

MD & Group CEO (additional director)

Appointed 1 Jul 2026

Filing

Alisha Moopen

Promoter director

Continuing

Choice India board page

Neeraj Jain

Independent Director

Appointed 1 Jul 2026

FilingReader

Kewal Handa

Independent Director

Appointed 1 Jul 2026

FilingReader

V K Mathews

Independent Director

Appointed 1 Jul 2026

FilingReader

Ayshwarya Vikram

Non-Executive Director (Blackstone-side, inferred)

Appointed 1 Jul 2026

FilingReader

Ganesh Mani

Non-Executive Director (Blackstone-side, inferred)

Appointed 1 Jul 2026

FilingReader

Neela Bhattacherjee

Independent Director

Appointed 28 Sep 2026

Screener announcements

Purana Housdurgam Vijayadeepti

Independent Director

Retired 28 Sep 2026

Screener announcements

M Madhavan Nambiar

Independent Director

Resigned 1 Jul 2026

FilingReader

C J George

Independent Director

Resigned 1 Jul 2026

FilingReader

Zeba Azad Moopen

Non-Executive (promoter family)

Resigned 1 Jul 2026

FilingReader

A further non-executive director (surname "Haji" per filing fragment)

Non-Executive

Resigned 1 Jul 2026

NSE filing fragment

Major Shareholders

Holder / categoryStake (%)As ofSource

Promoter and promoter group (total, foreign)

53.71

Jul 2026

IIFL shareholding

of which BCP Asia II Topco IV Pte. Ltd. (Blackstone), with persons acting in concert

29.71

Jul 2026

SAST disclosure

of which Aster promoters (Moopen family), merger-agreed level

About 24.0

Jul 2026

CRISIL rationale

Centella Mauritius Holdings (TPG)

9.90

Jul–Sep 2026

Centella correction disclosure (ScanX)

Institutions (aggregate, non-promoter)

26.79

Jul 2026

IIFL

Promoter holding before merger

40.39

Mar–Jun 2026

IIFL; Choice India

FII / DII before merger

10.53 / 0.41

Pre-merger 2026

Choice India

Retail before merger

21.42

Pre-merger 2026

Choice India

Competitive Landscape

Key Competitors

CompetitorOverlap with Aster DM Quality CarePositioning

Apollo Hospitals Enterprise

Pan-India, incl. Hyderabad, Bengaluru, Chennai

Largest chain: 76 hospitals, 10,970 licensed beds; FY26 revenue INR 25,228 crore [Src: Upstox]

Manipal Health Enterprises

Bengaluru (home market) and pan-India

FY26 revenue INR 10,335 crore (+25.4%) [Src: Upstox]

Max Healthcare Institute

Limited direct overlap (North/West India); ARPOB benchmark

17 hospitals, 6,131 beds; ARPOB about INR 77,800 [Src: Upstox]

Fortis Healthcare

Bengaluru and others

TTM revenue INR 9,506 crore [Src: Value Research]

Narayana Health (Narayana Hrudayalaya)

Bengaluru; cardiac and affordable tertiary

TTM revenue INR 9,072 crore [Src: Value Research]

Krishna Institute of Medical Sciences (KIMS, listed)

Direct in Telangana and Andhra Pradesh vs CARE and Aster Ramesh/Prime

Q2 FY26 revenue +23.6% YoY [Src: EY newsletter]

Global Health (Medanta)

Expanding into Central/East India (Indore, Lucknow, Patna)

Market cap about INR 39,800 crore [Src: Screener]

Rainbow Children's Medicare

Hyderabad and Bengaluru paediatrics/women's care vs the planned Aster W&C Hyderabad

Market cap about INR 14,700 crore [Src: Screener]

Yashoda Hospitals (unlisted)

Hyderabad

—

Kerala peers (VPS Lakeshore, Rajagiri, Amrita, Baby Memorial, Meitra)

Kerala cluster

—

Dr. Agarwal's Health Care, Park Medi World, Yatharth

Adjacent listed comparables

Smaller scale

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAster DM Quality CareApollo HospitalsFortis HealthcareMax HealthcareNarayana Health

Revenue TTM (INR Cr)

4,87626,4309,5068,7129,072

Net profit TTM (INR Cr)

402.492,127.31,052.41,457.4823.59

Net margin (%)

8.047.9911.0116.419.02

ROE (%)

7.7522.6611.0514.3920.09

P/E (x)

214.9459.6665.5665.8046.55

Market cap (INR Cr)

68,496124,66168,70195,86837,993

R&D intensity (%)

00000

Company Snapshot

45,000

Employees

1987

Founded

Bengaluru, India

Headquarters

Key Developments

DateEventSignificance
15–16 Apr 2025CCI approves Aster–QCIL transaction Angel One; ReutersRemoves competition-law gating item
~30 Apr–1 May 2025Aster completes 5% QCIL stake acquisition via share swap Indian Pharma PostFirst legal step of merger
May–Jun 2025Q4 FY25: revenue INR 1,000.34 crore; net profit INR 85.54 crore; FY25 revenue INR 4,138 crore Outlook BusinessRe-based India growth of 12%
Jun 2025Plan to add about 2,100 Aster beds for about INR 1,900 crore; combined target about 13,600 beds Towards HealthcareCapex visibility
Aug 2025Q1 FY26: revenue INR 1,078 crore (+8% YoY); net profit INR 85.52 crore TradingView/IIFLSoft quarter (Kerala)
2 Oct 2025Aster MIMS Kasaragod commences Q2 FY26 presentationNorth Kerala capacity
3 Oct 2025ICRA upgrades to A+ (Watch Positive); A1+ short-termCredit improvement
6 Nov 2025Q2 FY26: revenue INR 1,197 crore (+10%); operating EBITDA INR 263 crore (22.0%); stock-exchange no-objection letters received FilingReader; companyKerala turnaround; merger progress
10 Nov 2025PL Capital: BUY, TP INR 775Sell-side support
27 Jan 2026NCLT Hyderabad orders shareholder and creditor meetings TaxTMILegal path cleared
2 Feb 2026Q3 FY26: revenue INR 1,186 crore (+13%); pro-forma INR 2,366 crore (+15%), EBITDA INR 503 crore TaxTMISteady execution
10 Mar 2026Board approves Azad Moopen as Executive Director from 15 Apr 2026 CB InsightsFounder role formalised
~12 Mar 2026Shareholders and unsecured creditors approve merger (about 96.68% of votes) CB Insights; AskFuzzStrong minority support
25 Mar 2026GST order (Kochi): about INR 72.91 lakh on insurance processing fees, FY20–FY24 NSE filing; ScanXImmaterial tax dispute
26 Mar 2026Interim dividend of INR 3 per share (record ~3 Apr 2026) 5paisa; Anand RathiModest payout
27 Mar 2026Investor meeting (ICICI Securities, Bengaluru) ScanXIR activity
1 Apr 2026INR 4,000 crore plan to add 4,080 beds; 14,710 beds by FY28 Outlook Business; DigitalHealthNewsCapex escalation
30 Apr 2026Q4 FY26: revenue INR 1,182 crore (+18%); FY26 revenue INR 4,643 crore; operating EBITDA INR 947 crore; PAT INR 464 crore; pro-forma INR 9,273 crore / INR 2,013 crore Company release; ScanXYear-end benchmark
3–4 Jun 2026BofA and Citi India investor conferences ScanXIR
29 Jun 2026INR 25 crore OCRPS investment in Alfaone Medicals ScanXPharmacy associate support
1 Jul 2026Merger effective; board reconstituted; Varun Khanna MD & Group CEO; four directors resign Exchange filingsTransformational
3 Jul 2026Name change to Aster DM Quality Care Limited ScreenerIdentity
6–14 Jul 2026BCP allotted 244,996,597 shares; stake 29.71%; classified promoter; share count 871.7 million SAST disclosuresControl structure
10 Jul 2026ICRA upgrades to AA (Stable); rated amount up to INR 1,827 crore NSE filing; FilingReaderCredit step-up
18–19 Jul 2026Hitesh Dhaddha exits; Sunil Kumar M R named Group CFO & Head of IR FilingReaderCFO continuity
29–30 Jul 2026CRISIL assigns AA+ (Stable) / A1+ on novated QCIL facilities CRISIL; NSE filingHigher-tier rating
5 Aug 2026Q1 FY27: pro-forma revenue INR 2,597 crore (+20%); EBITDA INR 576 crore (+30%, 22.2%); INR 109.79 crore exceptional merger costs (standalone) Press release; filingsStrong first combined quarter
21 Aug 2026ICICI Direct TP INR 895 (28x FY28E EBITDA of INR 2,872 crore)Sell-side support
~Sep 2026BCP pledges 29.71% stake for USD 750 million loan; Centella corrects stake to 9.90% ScanXPromoter leverage
19 Sep 2026AGM addendum: INR 6,900 crore capital deployment over FY27–FY29 InvestywiseCapital allocation clarity
28 Sep 202618th AGM; Neela Bhattacherjee appointed ID; Vijayadeepti retires ScreenerGovernance
1 Oct 2026Trading window closed ahead of Q2 FY27 results TipRanksQ2 results imminent
14 Oct 2026AGM transcript published: no further dividend or bonus plans; 15,000-bed target Whalesbook; ScreenerPolicy signal

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2024–FY2026): Revenue from operations rose from INR 36,990 Mn in FY2024 to INR 46,430 Mn in FY2026.
Aster DM Healthcare Limited — Revenue by Segment (FY2024–FY2026)
Series (INR Mn)FY2024FY2025FY2026
Revenue from operations36,99041,38046,430
Operating EBITDA, company-defined—8,0609,470

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.